Allen Khodab, MD discussed how patients with larger prostates had reduced IPSS scores that normalized to the same level as those with normal-sized glands.

Leah Katz, MD, MPH, explained how an intraoperative tumor bed boost in TARGIT-B may reduce distant relapse in young patients with breast cancer.

Leah Katz, MD, MPH, discusses long-term IDEA trial data on omitting radiation and why endocrine therapy tolerance matters in this decision.

Alexandra Dreyfuss, MD, MS, explains why CAR T and bispecific populations are her priority for prospective radiotherapy studies in multiple myeloma.

Alexandra Dreyfuss, MD, MS, weighs bridging vs consolidative radiotherapy strategies around CAR T-cell infusion in myeloma.

“What we have here, I believe, is a strong signal that there is a population…who will benefit from chemotherapy,” said Mark D. Hurwitz, MD, FASTRO, FACRO.

Erik Bengtsen, MD, discussed meaning-centered therapy at the bedside, framing psychiatry referrals, and a more humanistic approach to care.

Ursula A. Matulonis, MD, surveyed the exploitable genetic changes driving the next wave of ovarian cancer trials, from CDK2 and WEE1 inhibitors to PARG inhibitors.